What is Vosoritide?

A 39-amino-acid analog of C-type natriuretic peptide (Voxzogo) studied in achondroplasia.

Vosoritide in the library · · Human Trials · What are peptides?

18 registered trials · 13 indexed papers · 13 human / 0 animal studies

From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.

What it is

A 39-amino-acid analog of C-type natriuretic peptide (Voxzogo) studied in achondroplasia.

Type: C-type natriuretic peptide analog.

Human research

The registered human trials and peer-reviewed human studies linked below are listed from ClinicalTrials.gov and PubMed. A study is linked only when Vosoritide is one of its interventions, or is named in the study title or subject headings.

Listing a study does not mean it showed a benefit, and it is not medical advice.

Registered human trials (18)

TrialPhaseStatusYearEnrolled
Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With AchondroplasiaPhase 2/Phase 3recruiting2026160
Long-Term Extension Study of Vosoritide to Treat Children With HypochondroplasiaPhase 3enrolling by invitation2025140
A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 MonthsPhase 2recruiting202560
A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone TreatmentPhase 2active not recruiting202430
A Phase 2 Study of Vosoritide in Children With Idiopathic Short StaturePhase 2recruiting2024100
Interventional Study of Vosoritide for the Treatment of Children With HypochondroplasiaPhase 3active not recruiting202480
Vosoritide for Short Stature in Turner SyndromePhase 2unknown202420
Safety and Efficacy of Voxzogo for Growth Deficits in MPS IVA and VIPhase 1/Phase 2active not recruiting20236
Bioequivalence Study to Compare Two Injection Devices for BMN 111 in Healthy ParticipantsPhase 1terminated202336
Vosoritide for Selected Genetic Causes of Short StaturePhase 2active not recruiting202056
A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With AchondroplasiaPhase 2active not recruiting202020
An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With AchondroplasiaPhase 2active not recruiting201973
A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With AchondroplasiaPhase 2completed201875
An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With AchondroplasiaPhase 3active not recruiting2017119
A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)Phase 2active not recruiting201630
A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With AchondroplasiaPhase 3completed2016121
A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With AchondroplasiaPhase 2completed201435
A Study to Evaluate Safety and Tolerability of BMN 111 Administered to Healthy Adult VolunteersPhase 1completed201274

Peer-reviewed studies (13)

PaperAuthorsJournalYearType
Real-World Outcomes of Vosoritide Treatment in Chinese Children with Achondroplasia: The Retrospective Cohort COREV StudyChen L et al.Advances in therapy2026Observational Study
A phase II basket trial of vosoritide in children with RASopathies, ACAN, and NPR2 deficiencyDauber A et al.The Journal of clinical endocrinology and metabolism2026Clinical Trial, Phase II
Development of Muscle Function in Children with Achondroplasia Under Vosoritide Treatment: A Retrospective Single-Centre Observational StudyReincke S et al.Journal of musculoskeletal & neuronal interactions2026Observational Study
Effect of Vosoritide Therapy on IGF-I and Endogenous C-Type Natriuretic Peptide in HypochondroplasiaKanakatti Shankar R et al.The Journal of clinical endocrinology and metabolism2026Clinical Trial, Phase II
Phase 2 Trial of Vosoritide Use in Patients with Hypochondroplasia: A Pharmacokinetic/Pharmacodynamic AnalysisGaletaki D et al.Hormone research in paediatrics2026Clinical Trial, Phase II
Sustained growth-promoting effects of vosoritide in children with achondroplasia from an ongoing phase 3 extension studySavarirayan R et al.Med (New York, N.Y.)2025Randomized Controlled Trial
Persistent growth-promoting effects of vosoritide in children with achondroplasia are accompanied by improvements in physical and social aspects of health-related quality of lifeSavarirayan R et al.Genetics in medicine : official journal of the American College of Medical Genetics2024Randomized Controlled Trial
Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trialSavarirayan R et al.The Lancet. Child & adolescent health2024Randomized Controlled Trial
Pharmacokinetics and Exposure-Response of Vosoritide in Children with AchondroplasiaChan ML et al.Clinical pharmacokinetics2022Randomized Controlled Trial
Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension studySavarirayan R et al.Genetics in medicine : official journal of the American College of Medical Genetics2021Randomized Controlled Trial
Rationale, design, and methods of a randomized, controlled, open-label clinical trial with open-label extension to investigate the safety of vosoritide in infants, and young children with achondroplasia at risk of requiring cervicomedullary decompression surgerySavarirayan R et al.Science progress2021Clinical Study
Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trialSavarirayan R et al.Lancet (London, England)2020Randomized Controlled Trial
C-Type Natriuretic Peptide Analogue Therapy in Children with AchondroplasiaSavarirayan R et al.The New England journal of medicine2019Clinical Trial, Phase II

Conditions researched

Related compounds

FAQ

What is Vosoritide?

A 39-amino-acid analog of C-type natriuretic peptide (Voxzogo) studied in achondroplasia.

How many registered human trials study Vosoritide?

The PeptideWhiz trial index lists 18 registered trials for Vosoritide, the most recent from 2026.

How much published research exists on Vosoritide?

The PeptideWhiz paper index links 13 PubMed papers to Vosoritide; by study type, 13 human and 0 animal studies.

Which conditions is Vosoritide researched for?

Post-surgical inflammation and surgery recovery.

Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).

Reported dosing ranges from research